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Lysosomal storage diseases (LSDs) are inherited metabolic disorders caused by either lysosomal or non-
lysosomal proteins deficiencies and often showing a severe neurodegenerative course. No cure is currently 
available to slow neuropathology progression in these diseases. Neurodegeneration in LSDs is driven by a 
global dysfunction of the lysosomal system, in particular of autophagy pathway. Such lysosomal dysfunction 
is associated to progressive accumulation of several types of substrates, whose nature and pathogenic 
relevance remain, however, still unclear. Here we found that massive amyloid deposition characterizes brain 
pathology in several mouse models of LSDs. Brain amyloid deposits progressively build up as 
neurodegeneration proceeds as shown by analyzing a mouse model of neurodegenerative LSDs. Such amyloid 
inclusions contain α-synuclein together with several other aggregate-prone proteins, such as prion protein, 
Tau and amyloid ß-peptide. A major fraction of these amyloid deposits is localized to the lysosomal 
compartment where they act as main determinants of lysosomal dysfunction, thus boosting the development 
of neurodegenerative phenotype. Indeed, inhibiting amyloid deposition in MPS-IIIA mice by CLR01, a 
“molecular tweezer” molecule, which efficiently hamper self-assembly of multiple amyloidogenic proteins 
relieves lysosomal pathology, thus re-activating lysosomal-autophagic pathway and ameliorating 
neuropathological signs. Together, these data put more insights on mechanisms determining amyloid 
aggregation toxicity and identify LSDs as a new class of amyloid disorders. Moreover, our results identify CLR01 
as a potent drug candidate for the treatment of brain lesions in LSDs.  
 
